Table 2

Patient characteristics (hospitalised)

	Unvaccinated (reference)		Double-vaccinated		Triple-vaccinated		P value
	n	%	n	%	n	%	P value
	142		44		22
Age (years, median, range)	65 (19–93)		65 (28–86)		67 (41–87)		0.685*
Female	89	62.7	23	52.3	18	81.8	0.065†
Body mass index (median, range)	27.9 (18–46)		27.6 (19–43)		26.45 (18–42)		0.560*
1. Vaccine
Moderna			1	2.3	2	9.1
Pfizer/BioNTech			34	77.3	16	72.7
AstraZeneca			3	6.8	2	9.1
Janssen/Johnson&Johnson			0	0	0	0
Nuvaxovid			0	0	0	0
Unknown			6	13.6	2	9.1
2. Vaccine
Moderna			3	6.8	2	9.1
Pfizer/BioNTech			35	79.5	16	72.7
AstraZeneca			4	9.1	0	0
Janssen/Johnson&Johnson			0	0	0	0
Nuvaxovid			0	0	1	4.5
Unknown			2	4.5	3	13.6
3. Vaccine
Moderna					‡	13.6
Pfizer/BioNTech					14	63.6
AstraZeneca					0	0
Janssen/Johnson&Johnson					0	0
Nuvaxovid					0	0
Unknown					5	22.7
Time between SARS-CoV-2 infection and last vaccination (days, median, range)			149.5 (17–307)		78.5 (22–120)
IRD (multiple selection possible)
Rheumatoid arthritis	79	55.6	18	40.9	12	54.5	0.227†
Spondyloarthritis	22	15.5	6	13.6	1	4.5	0.490‡
Connective tissue diseases	15	10.6	10	22.7	4	18.2	0.091‡
Other vasculitides	9	6.3	3	6.8	1	4.5	1.000‡
ANCA-associated vasculitis	14	9.9	7	15.9	4	18.2	0.326‡
Other type of IRD	13	9.2	2	4.5	2	9.1	0.667‡
Immunomodulation (multiple selection possible)
Glucocorticoids	72	50.7	23	52.3	15	68.2	0.310†
Prednisolone ≤5 mg/day	53	37.3	14	31.8	11	50.0
Prednisolone 6–9 mg/day	1	0.7	1	2.2	0	0
Prednisolone ≥10 mg/day	12	8.5	5	11	1	4.5
Methotrexate, leflunomide, sulfasalazine	84	59.1	24	54.5	10	45.5	0.457†
Azathioprine	6	4.2	1	2.3	0	0	1.000‡
Tumour necrosis inhibitors (adalimumab, certolizumab, infliximab, golimumab)	16	11.3	4	9.1	3	13.6	0.833‡
Other cytokine inhibitors (IL-6/IL-1/IL12/23/IL17 inhibition)	5	3.5	3	6.8	2	9.1	0.124‡
Janus kinase inhibitors (baricitinib, tofacitinib, upadacitinib, filgotinib)	14	9.9	5	11.4	1	4.5	0.404‡
Immunsuppressives (cyclosporine, mycophenolate, cyclophosphamide)	4	2.8	5	11.4	2	9.1	0.046‡
Abatacept	3	2.1	2	4.5	2	9.1	0.109‡
Rituximab	16	11.3	15	34.1	7	31.8	0.001†
Belimumab	1	0.7	0	0	0	0
Immunoglobulins	1	0.7	0	0	1	1.0
Other immunmodulators	5	3.5	1	2.3	0	0
No immunmodulation	9	6.3	2	4.3	0	0
Disease activity
No/low	111	78.2	30	68.2	20	90.9	0.106†
Moderate/high	21	14.8	14	31.8	2	9.1	0.026‡
Comorbidities (multiple selections possible)
Arterial hypertension	74	52.1	26	59.1	12	54.5	0.718†
Other relevant comorbidities	47	33.1	17	38.6	6	27.3	0.634†
Heart failure/arrhythmia	34	23.9	17	38.6	6	27.3	0.162†
Diabetes mellitus	31	21.8	4	9.1	2	9.1	0.015‡
Osteoporosis	14	9.9	6	13.6	5	22.7	0.210†
Chronic renal failure	27	19.0	7	15.9	6	27.3	0.540†
Cancer/history of cancer	8	5.6	4	9.1	1	4.5	0.398‡
Chronic obstructive lung diseases	5	3.5	4	9.1	0	0	0.379‡
Interstitial lung diseases	9	6.3	6	13.6	3	13.6	0.149‡
Bronchial asthma	10	7.0	1	2.3	3	13.6	0.192‡
Pregnancy	2	1.4	0	0	0	0
Pulmonal hypertension	1	0.7	1	2.3	1	4.5
Liver cirrhosis	2	1.4	0	0	0	0
Absence of relevant comorbidities	21	14.8	7	15.9	2	9.1	0.785‡
COVID-19-associated complications
Invasive ventilation	25	17.6	11	25.0	1	4.5	0.112‡
Relevant complications (eg, concomitant infection, thromboembolic events)	50	35.2	19	43.2	4	18.2	0.128‡
COVID-19-related death	18	12.7	10	22.7	5	22.7	0.182†

*Kruskal-Wallis test.
†χ² test (Pearson).
‡Fisher’s exact test.
IRD, inflammatory rheumatic disease.